Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Capricor Therapeutics (CAPR) over the last 11 years, with Q3 2025 value amounting to $9.9 million.

  • Capricor Therapeutics' Accumulated Expenses changed N/A to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year change of. This contributed to the annual value of $4.9 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Capricor Therapeutics' Accumulated Expenses stood at $9.9 million.
  • Capricor Therapeutics' 5-year Accumulated Expenses high stood at $9.9 million for Q3 2025, and its period low was $4.2 million during Q1 2025.